CONCORD BIOTECH LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,470 INR | +1.73% |
|
+1.12% | -0.13% |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 151,139 | - | - |
| Enterprise Value (EV) 1 | 159,100 | 148,455 | 147,174 |
| P/E ratio | 51.6 x | 38.7 x | 30.3 x |
| Yield | 0.43% | 0.69% | 0.87% |
| Capitalization / Revenue | 15.6 x | 12.1 x | 9.95 x |
| EV / Revenue | 15.6 x | 11.9 x | 9.69 x |
| EV / EBITDA | 36.9 x | 27.8 x | 21.9 x |
| EV / FCF | 165 x | 55.9 x | 45.7 x |
| FCF Yield | 0.61% | 1.79% | 2.19% |
| Price to Book | 9.87 x | 8.29 x | 6.86 x |
| Nbr of stocks (in thousands) | 104,616 | - | - |
| Reference price 2 | 1,445 | 1,445 | 1,445 |
| Announcement Date | 5/24/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 10,169 | 12,453 | 15,192 |
| EBITDA 1 | - | 4,316 | 5,344 | 6,728 |
| EBIT 1 | - | 3,780 | 4,814 | 6,159 |
| Operating Margin | - | 37.17% | 38.65% | 40.54% |
| Earnings before Tax (EBT) 1 | - | 4,126 | 5,137 | 6,580 |
| Net income 1 | 2,401 | 3,081 | 3,913 | 5,002 |
| Net margin | - | 30.3% | 31.42% | 32.93% |
| EPS 2 | 22.95 | 29.45 | 37.38 | 47.72 |
| Free Cash Flow 1 | - | 911.5 | 2,655 | 3,223 |
| FCF margin | - | 9.19% | 21.32% | 21.22% |
| FCF Conversion (EBITDA) | - | 21.56% | 49.68% | 47.91% |
| FCF Conversion (Net income) | - | 30.29% | 67.84% | 64.43% |
| Dividend per Share 2 | - | 6.280 | 9.900 | 12.53 |
| Announcement Date | 7/1/23 | 5/24/24 | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 630 | 2,685 | 3,965 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | 912 | 2,655 | 3,223 |
| ROE (net income / shareholders' equity) | - | 21.4% | 22.9% | 24.4% |
| ROA (Net income/ Total Assets) | - | 19% | 20% | 22% |
| Assets 1 | - | 15,837 | 19,566 | 22,739 |
| Book Value Per Share 2 | - | 146.0 | 174.0 | 211.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 1,433 | 550 | 600 |
| Capex / Sales | - | 14.45% | 4.42% | 3.95% |
| Announcement Date | 7/1/23 | 5/24/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,445
INR
Average target price
1,592
INR
Spread / Average Target
+10.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.13% | 1.81B | |
| +0.85% | 92.4B | |
| -3.16% | 38.08B | |
| -9.63% | 34.05B | |
| +71.42% | 27.77B | |
| -12.63% | 16B | |
| -0.16% | 14.1B | |
| -9.38% | 11.91B | |
| +172.59% | 10.37B | |
| -49.44% | 10.2B |
- Stock Market
- Equities
- CONCORDBIO Stock
- Financials Concord Biotech Limited
